CoChat

Can Mendelian Randomization Shift into Reverse Gear?

Open access
Holmes, Michael V, Davey Smith, George · 2019 · Clinical Chemistry
Cited by 67

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Mendelian randomization (MR),7 a genetic epidemiological approach, has made substantial inroads into our understanding of the causes, and consequences, of disease (1, 2). Conventionally, MR takes genetic variants associated with an exposure to estimate the causal effect on risk of disease. Availability of large-scale data and hypothesis-free genome-wide analyses has led to discovery of trait-associated genetic variants that surpass stringent thresholds for multiple testing correction, making genome-wide association study (GWAS) discoveries among the most reliable (i.e., among the least prone to false positives) in the scientific literature. A naïve criticism of GWAS is that the discoveries made therein have limited translational utility. Combining GWAS-identified single-nucleotide polymorphisms (SNPs) into genetic instruments under the MR approach, however, offers translational opportunities, yielding notable discoveries for public health and, in the longer-term, pharmaceutical development. More immediate translational opportunities include pharmacogenetics (3) and the emerging use of GWAS for disease prediction (4). In the case of MR, recent examples include identifying that genetic liability to diabetes causes erectile dysfunction (5) and that alcohol consumption may not protect from vascular disease (6). The elucidation of these would be seemingly unachievable under other study designs, e.g., the NIH-funded Moderate Alcohol and Cardiovascular Health trial (MACH15; NCT03169530) was abandoned because of perceived influence and bias from Big Alcohol (7). As with all scientific investigations, MR studies can be influenced by unique forms of bias, confounding, and analytical inaccuracies—what differentiates MR from conventional epidemiology is the availability of multiple sensitivity analyses (1, 8), enabling scientists to test many of the implicit assumptions. In this issue of Clinical Chemistry, Mohammadi-Shemirani and colleagues (9) have turned MR on its head. They propose taking a summary score of genetic variants robustly associated with estimated glomerular filtration rate (eGFR), a trait used to assess renal function, and relating this to a range of potential biomarkers. Taking 50 eGFR-associated SNPs in combination, they found an association with concentrations of the protein trefoil factor (TFF3). Importantly, cis-acting protein quantitative trait loci (pQTLs) did not demonstrate a causal effect of TFF3 on eGFR, suggesting that the biomarker identified was not a cause, but possibly a consequence of eGFR. A disease-associated genetic risk score (GRS) would be expected to associate with causes of the disease, consequences of the process leading to the disease, or the disease itself. For example, a GRS for lung cancer that included cholinergic receptor nicotinic alpha 5 subunit (CHRNA5)8 variants related to heaviness of smoking would be expected, therefore, to associate with smoking behavior. It is also possible that a GRS for a disease might identify biomarkers that are influenced by the process leading to disease or by the disease itself. In this case, if MR of the biomarker suggests that the biomarker does not cause disease (as in the study by Mohammadi-Shemirani and colleagues (9)), the biomarker may be a good candidate to investigate for disease prediction. What do biomarker associations of SNPs combined into a GRS that were originally identified for disease (or a precursor of disease) actually mean? We consider these to represent at least 7 scenarios (see Fig. 1), which we elucidate below and in the figure: note that we do not consider these to be exhaustive. Scenarios 1–4 represent “real” GRS-to-trait associations, whereas scenarios 5–7 represent potential artifacts owing to analytical method, study design, or diagnostic approach to disease. The 7 scenarios are described in the main text. Purple cloud call-outs elucidate whether the biomarker is likely to have a role in disease prediction and/or whether it represents a potential therapeutic target for the treatment and/or prevention of disease. First, the biomarker association of the GRS may represent a biomarker that causes disease. An example of this would be proprotein convertase subtilisin/kexin type 9 (PCSK9) genetic variants that associate with coronary heart disease (CHD) at GWAS significance, and which pinpoint LDL-cholesterol as being on the causal pathway to risk of CHD. A GRS-associated biomarker in this scenario may have predictive utility and could also represent a therapeutic target for disease prevention. Second, disease–GRS associations with a biomarker may represent a consequence of disease, akin to the conventional epidemiological phenomenon of “reverse causality.” For example, a GRS for CHD is associated with a higher likelihood of receiving statin therapy (analyzed in MR-Base (10) on December 8th, 2018). A naïve interpretation would be that statin therapy leads to a higher risk of CHD, but of course this is not the case: indiv

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2018.296806

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 67

Metadata

Authors
Holmes, M. V., & Davey Smith, G.
Venue
Clinical Chemistry
Published
2019-03-01
Volume
65
Issue
3
Pages
363-366
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2912798069
Cited by
67
References
7
FWCI
2.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Can Mendelian Randomization Shift into Reverse Gear? https://app.cochat.ai/papers/10.1373/clinchem.2018.296806
The paper
Holmes, M. V., & Davey Smith, G. (2019). Can Mendelian Randomization Shift into Reverse Gear? Clinical Chemistry. https://doi.org/10.1373/clinchem.2018.296806

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.